ARA-290 Peptide For Sale
Buy ARA-290 peptide: 10mg, 16mg, 30mg or 160mg listed purchase quantities. Compare live prices across 8 listed vendors with real cost per mg, recorded COA availability and discount codes.
Buy ARA-290 peptide starting at $35.00/purchase from 8 listed vendors. Compare 10mg, 16mg, 30mg and 160mg purchase quantity options by cost per mg, price per purchase, monthly cost, discount codes and recorded COA metadata (not independent verification).
How much does ARA-290 cost per month?
An illustrative ARA-290 cost model works out to about $408.78 per month: Peptira's listed 30 mg purchase quantity at $101.15 with code WPA, divided into 4 mg amounts daily. This quantity provides 7.5 nominal portions — about 1.1 weeks at the selected cadence, before preparation losses or stability limits — for roughly $94.41 per week or $408.78 per 4.33-week month. Vial count and milligrams per vial must be checked separately. This is illustrative arithmetic combining independently selected lifetime modal inputs, not a verified most-common joint protocol. The amount distribution includes 499 calculator runs; overall cadence comes from 97 separate lifetime frequency responses across amounts. Calculator inputs are not confirmed administration or recommendations.
Use the live cost-per-month card to change nominal purchase quantity, amount, cadence and vendor strategy. Recorded purity can be compared separately; it is not independent verification or a quality guarantee. Confirm package composition and checkout price with the vendor.
About ARA-290
In clinical trialsAlso known as: Cibinetide · CibinitideARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin, most often sourced for neuropathic-pain and tissue-repair research. It was engineered to keep EPO's tissue-protective signal without raising red-blood-cell counts. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]
What to check before you buy ARA-290:
- A third-party COA showing ≥98% purity by HPLC plus mass-spec confirmation of the 11-amino-acid sequence — not just an in-house "lab tested" claim.
- A COA dated within the last 6–12 months that matches the exact vial size and batch you are buying.
- Accurate vial fill matching the label; under-filled vials are a common failure mode that skews reconstitution math.
A Phase 2 trial in sarcoidosis-associated small-fiber neuropathy (Heij et al., Mol Med 2017) reported improvements in neuropathic pain and small-fiber metrics versus placebo after 28 days.[3] Additional Phase 2 work in chronic neuropathic pain, ophthalmologic dry-eye disease, and diabetic macular edema has been reported by Araim, with mixed results across endpoints.
Regulatory: Not FDA-approved. Phase 2 trials by Araim Pharmaceuticals in neuropathic pain, sarcoidosis SFN, and dry-eye indications; no Phase 3 program initiated. Research-grade material only.
ARA-290: Mechanisms, Half-Life & Research Data
A skimmable deep dive into how ARA-290 works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.
How it works
ARA-290 (cibinetide) is an 11-amino-acid linear peptide whose sequence was lifted from helix B of human erythropoietin (EPO) by the Brines/Cerami group at Araim Pharmaceuticals.[1] The design rationale is unusual and important: EPO has two distinct biological activities – the well-known hematopoietic activity (red-blood-cell production) mediated by homodimeric EPO receptors on erythroid precursors, and a separate tissue-protective and anti-inflammatory activity mediated by a heteromeric receptor formed by the EPO receptor and the β-common (CD131) receptor that the Brines group named the "innate repair receptor" (IRR).[2][7] Cibinetide binds the IRR but **not** the homodimeric EPOR – so it produces EPO's tissue-protective and anti-inflammatory effects (reducing neuronal injury, dampening inflammatory cytokine release, supporting small-fibre nerve regeneration) without raising hematocrit or red-cell mass.[1][2][7] This is what makes chronic dosing tolerable in a way that recombinant EPO is not. Plasma half-life is short (minutes), but the downstream IRR-mediated tissue-protective effect persists for hours. Phase 2 protocols have used 1–4 mg/day subcutaneous for courses of 28 days.[3][6]
Active research areas
- Sarcoidosis-associated small-fibre neuropathyThe most-developed indication. Heij and colleagues ran a Phase 2 randomised double-blind pilot reporting reduced neuropathic-pain scores and improved small-fibre metrics after 28 days,[3] and a follow-up 2017 paper showed measurable improvement in corneal nerve fibre abundance – an objective imaging endpoint – after cibinetide treatment.[4] An expert-opinion review summarised the field through 2014.[5]
- Type 2 diabetes neuropathy and metabolic controlBrines and colleagues reported a Phase 2 study showing that ARA-290 improved metabolic control and reduced neuroautonomic symptoms in patients with type 2 diabetes – a dual signal of glycaemic and small-nerve-fibre benefit that motivates the broader neuropathic-pain program.[6]
- Chronic neuropathic pain (cross-aetiology)
- Ophthalmologic / corneal nerve regenerationThe 2017 corneal-confocal-microscopy work demonstrated measurable corneal sub-basal nerve fibre regeneration after cibinetide treatment in sarcoidosis SFN patients,[4] which has motivated additional exploratory work in dry-eye and ocular surface disease that has not yet reached pivotal-trial scale.
- Cardiac, renal, and retinal tissue protection (pre-clinical)A broad pre-clinical literature reports that cibinetide and related IRR agonists protect cardiac, renal, retinal, and CNS tissue from ischemia-reperfusion and chronic inflammatory injury through mechanisms convergent with the small-fibre work.[1][2][7] None of these have advanced to confirmatory human trials.
Open questions & leading hypotheses (2)
- Hypothesis: The Phase 2 sarcoidosis-SFN benefit will hold up in a properly powered Phase 3 program.Evidence: The 2012 pilot trial and the 2017 corneal-imaging follow-up showed converging signals on both subjective neuropathic-pain scores and objective small-fibre regeneration metrics – unusual for a Phase 2 program in a notoriously difficult-to-measure indication.[3][4][5] Counter-evidence: no Phase 3 trial has been initiated 12+ years after the original pilot, despite a positive signal – which can reflect funding constraints rather than efficacy doubt, but the gap is itself information; the published cohorts are also small, and small-fibre neuropathy has a substantial regression-to-the-mean component that complicates short-trial readouts.
- Hypothesis: The IRR is anatomically and pharmacologically distinct from the homodimeric EPOR – not just a low-affinity variant of EPOR binding.Evidence: Brines and Cerami have published extensively on IRR composition (EPOR + β-common heterodimer) and on the lack of erythropoietic effect of cibinetide at doses that produce clear tissue protection.[2][7] Counter-evidence: independent receptor-pharmacology groups have raised methodological questions about how cleanly the IRR can be isolated from EPOR signalling in vivo, and the molecular identity of "the" tissue-protective receptor remains an active area of debate outside the Brines/Cerami program.
What community users report
Anecdotal — not controlled-trial evidence
On r/Peptides and r/PeptideAdmin, ARA-290 use is comparatively narrow and explicitly clinical-feeling – most users running it have a small-fibre neuropathy, diabetic neuropathy, sarcoidosis, or chronic-fatigue / long-COVID complaint they are trying to address, rather than a longevity or recomposition motivation.[9][10] Reported protocols cluster around the published Phase 2 dose (typically 1–4 mg/day subcutaneous for 28-day courses), and reported effects are usually modest but consistent: gradual reduction in neuropathic burning/tingling pain, improved sleep, and – in a smaller cohort – reductions in autonomic complaints (orthostatic intolerance, dysautonomia). Side effects are infrequently reported and typically limited to injection-site irritation. **These reports are anecdotal and have not been validated in controlled trials.** They are consistent with the published Phase 2 efficacy signal in sarcoidosis SFN, but they do not establish that ARA-290 is safe or effective for any specific neuropathic or autonomic indication – that question requires a Phase 3 trial that has not yet been run.
Sources & references (10)
Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.
- [1]Brines M et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 2008;105:10925–10930. · PMID: 18676614 link
- [2]Brines M, Cerami A. The receptor that tames the innate immune response. Mol Med 2012;18:486–496. · PMID: 22183892 link
- [3]Heij L et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med 2012;18:1430–1436. · PMID: 23168581 link
- [4]Heij L, Niesters M, Swartjes M et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss. Invest Ophthalmol Vis Sci 2017;58. · PMID: 28475703 link
- [5]Eckersley L et al. ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opin Investig Drugs 2014;23:541–545. · PMID: 24555851 link
- [6]Brines M et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuroautonomic symptoms in patients with type 2 diabetes. Mol Med 2015;20:658–666. · PMID: 25387363 link
- [7]Brines M, Cerami A. Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacol Ther 2015;154:36–43. · PMID: 25728128 link
- [8]Niesters M et al. Assessment of allodynia relief by tissue-protective molecules in a rat model of nerve injury-induced neuropathic pain. Methods Mol Biol 2013. · PMID: 23456870 link
- [9]Community report – r/Peptides ARA-290 / cibinetide neuropathy threads (subreddit), accessed May 2026. link
- [10]Community report – r/PeptideAdmin ARA-290 protocol discussions (subreddit), accessed May 2026. link
What ARA-290 Costs Right Now
WPA currently tracks ARA-290 from 8 distinct vendors across 9 separate ARA-290 listings. In-stock ARA-290 vials run from $35 to $770.36 — a 22x spread for the same compound. Ascension Peptides holds the lowest sticker price at $35. Normalized to milligrams, ARA-290 costs $3.37/mg to $4.81/mg on this page. The best per-milligram value is the listed 30 mg purchase quantity from Peptira.
ARA-290 is stocked in 4 sizes: 10 mg listed quantity; vial count not recorded; 160 mg listed quantity; vial count not recorded; 16 mg listed quantity; vial count not recorded; 30 mg listed quantity; vial count not recorded. 8 of the 9 tracked listings are in stock right now. Because vials of different strengths rarely scale linearly in price, the per-milligram column is the only fair way to rank them.
Ranked by true cost per milligram, the ARA-290 listings WPA tracks are: Peptira — 30mg at $101.15 ($3.37/mg), COA purity 99.84%; Ascension Peptides — 10mg at $35 ($3.50/mg), COA purity 99.72%; Southern Aminos — 10mg at $41.65 ($4.17/mg), COA purity 99.86%; Glow Aminos — 10mg at $41.65 ($4.17/mg), COA purity 99.64%; Flawless Compounds — 10mg at $41.65 ($4.17/mg), COA purity 99.85%.
ARA-290 COA Coverage Across Tracked Vendors
6 of the 9 tracked ARA-290 listings (67%) are marked as having COA availability in WPA's listing data; this marker is not independent verification. A purity value is recorded for 6 listings; purity alone does not establish identity or independent testing. The recorded purity values range from 99.64% to 99.86%. 6 listings record more ARA-290 in the vial than the label claims; check the vendor's report and batch before drawing conclusions. The latest COA date recorded in WPA's listing data is 9/26.
To assess a COA, inspect the actual report for the independent lab, test date, and a batch and vial size matching the ARA-290 offer. WPA's listing fields do not establish that a report was independently verified.
ARA-290 Calculator Input Observations
In lifetime ARA-290 calculator inputs, 4mg is the most frequent entered amount (199 of 499 runs). Separately, Daily (7x/wk) is the most frequent overall cadence (31 of 97 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 4mg, Daily (7x/wk) is most frequent (9 of 16 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. As nominal quantity arithmetic only, 160 mg of listed product divided by 4 mg gives roughly 40 portions before preparation losses. This does not establish vial count, stability after preparation, or cycle length.
ARA-290 Discount Codes
9 of the 9 tracked ARA-290 listings carry a WPA researcher discount code. The largest live discount is 50% off. Every price and per-milligram figure on this page is the post-discount number, so you are never comparing a discounted listing against an undiscounted one. Codes change and some exclude sale items or carry order minimums.
About ARA-290
ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin, most often sourced for neuropathic-pain and tissue-repair research. It was engineered to keep EPO's tissue-protective signal without raising red-blood-cell counts. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
ARA-290 is tracked under the Recovery Peptides category on WPA. Its reported half-life is ~2 min (plasma). Calculator inputs do not establish why a cadence was selected or validate a protocol. Not FDA-approved.
How to Read the ARA-290 Comparison
- Price per milligram — Every ARA-290 listing is normalized to $3.37/mg-style unit pricing, so a small cheap vial cannot hide a worse real cost than a larger one.
- COA metadata and purity — 6 ARA-290 listings are marked for COA availability, and 6 have a recorded purity value. These fields do not independently verify a report.
- Vials sizes — The ARA-290 comparison includes 10mg, 16mg, 30mg, and 160mg listed purchase quantities. Check package composition separately.
- Stock status — Live in-stock state for each ARA-290 listing, refreshed on a recurring basis.
Frequently Asked Questions: ARA-290
Is it legal and safe to buy ARA-290 for research?
In the US, ARA-290 is sold strictly as a research chemical — legal to buy for laboratory research but not approved for human use. ARA-290 (cibinetide) is an investigational EPO-derived peptide with no approved human form, sold strictly for laboratory research. The real variable isn't legality, it's quality: unverified suppliers can ship underdosed, impure, or mislabeled material. WPA records COA-related listing fields where supplied, but does not independently verify every report. Inspect the actual batch report and its laboratory, identity testing, and date before drawing conclusions. Right now that screen covers 9 ARA-290 listings from 8 vendors, 8 of them in stock.
How do I verify a ARA-290 COA so I'm not getting an underdosed vial?
A Certificate of Analysis (COA) may report tests for a specific ARA-290 batch. Check that the report identifies the compound (actually ARA-290 (cibinetide), the 11-amino-acid EPO-derived peptide, not an underdosed or substituted vial), names the laboratory, describes the test method and result, and matches the offered batch and date. A recorded purity value or COA-availability flag in WPA's listing data is not independent verification. Open the vendor listing and inspect the actual report before drawing conclusions. For ARA-290 specifically, 6 of 9 tracked listings (67%) are marked as having COA availability in WPA's listing data; that marker is not independent verification. A purity value is separately recorded for 6 listings; purity alone does not establish identity or independent testing. The latest COA date recorded in the listing data is 9/26.
Which ARA-290 vendor should I pick?
There's no single "best" ARA-290 vendor — it depends on what you weigh most. WPA ranks tracked listings using recorded purity and date fields where available, visitor click activity, price, stock status, and discount data; this ranking is not independent verification of a report. 8 vendors currently carry ARA-290, and Peptira holds the best true value at $3.37/mg on the 30 mg listed purchase quantity. Review the actual report and confirm its batch details before making a decision.
How much does ARA-290 cost — and how do I know I'm not overpaying?
Judge ARA-290 by true price per milligram, not the sticker price on one vial — a cheap small vial often costs more per mg than a larger one. It most often ships in 16 mg vials, so compare $/mg across those rather than the sticker price on one vial. Tracked ARA-290 listings currently run $3.37/mg to $4.81/mg across 10mg, 16mg, 30mg, 160mg listed purchase quantities (not necessarily single vials). WPA normalizes tracked listings to $/mg, and the live cost-per-month card estimates your spend at the most common dose. The one catch: the lowest $/mg sometimes means buying a bigger vial than your cycle needs.
How much ARA-290 do I need for one full cycle?
In lifetime ARA-290 calculator inputs, 4mg is the most frequent entered amount (199 of 499 runs). Separately, Daily (7x/wk) is the most frequent overall cadence (31 of 97 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 4mg, Daily (7x/wk) is most frequent (9 of 16 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. Dividing the listed 160 mg purchase quantity by 4 mg gives roughly 40 nominal portions before preparation losses; vial count and stability after preparation are separate questions. A cycle requires an independently chosen amount, cadence and time horizon; calculator observations do not supply those decisions. Compare nominal package quantities and model your own selections in the cost card.
Are discount codes available for ARA-290?
Participating ARA-290 vendors may offer WPA researcher discount codes. Codes can change, exclude sale items or carry order minimums. 9 of the 9 tracked ARA-290 listings carry a code right now, the largest worth 50% off. Each listing shows the recorded code and discounted price where available; confirm the actual package and checkout terms with the vendor.
Where can I compare ARA-290 prices and listing details?
This comparison shows 9 tracked listings for ARA-290 in the selected format. Compare purchase price, established nominal quantities, discount terms and recorded COA availability, purity and date fields. Those fields are not independent verification. Inspect actual batch reports and confirm package composition and checkout price on the vendor's site.